- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| STRYKER CORPORATION CDR Aktie jetzt für 0€ handeln | |||||
| Fr | Stryker (SYK) is Buying ZuriMED. Can FiberLocker Strengthen its Shoulder Portfolio? | 6 | Insider Monkey | ||
| Do | Stryker Launches FDA-Cleared Apple Vision Pro Surgical App | 18 | Zacks | ||
| Di | Stryker führt erste Operation mit FDA-zugelassener App für Apple Vision Pro durch | 25 | Investing.com Deutsch | ||
| Di | Stryker completes first surgery using Apple Vision Pro app | 2 | Investing.com | ||
| Di | Stryker introduces first of its kind FDA-authorized surgical application for Apple Vision Pro with hip arthroscopy case at nationally recognized academic medical center | 257 | PR Newswire | SportSuite Vision brings spatial computing into the operating room, providing surgeons access to critical clinical information
Stryker announced the successful completion of the first... ► Artikel lesen | |
| Di | Is Stryker Stock Underperforming the Nasdaq? | 19 | Barchart.com | ||
| 31.08. | Stryker to acquire ZuriMed to boost shoulder offerings | 4 | MassDevice | ||
| 31.08. | Stryker to acquire ZuriMED and its rotator cuff repair system | 9 | Investing.com | ||
| 31.08. | Stryker Corporation: Stryker signs definitive agreement to acquire ZuriMED to enhance its shoulder offering | 532 | GlobeNewswire (Europe) | Portage, Mich., USA, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Stryker has signed a definitive agreement to acquire ZuriMED, developer of the FiberLocker System, a commercialized technology that provides... ► Artikel lesen | |
| 26.08. | Do Options Traders Know Something About Stryker Stock We Don't? | 18 | Zacks | ||
| 24.08. | US-Heer vergibt 54-Millionen-Dollar-Auftrag für Stryker-Fahrzeuge an General Dynamics | 20 | Investing.com Deutsch | ||
| 21.08. | Stryker Board Member Sold $117.78M In Company Stock | 24 | Benzinga.com | ||
| 19.08. | Thomas Kean Jr. trades in Alphabet, Amazon, and Stryker stocks | 13 | Investing.com | ||
| 18.08. | Stryker's unit wins $100M defense contract option for patient monitoring equipment | 10 | Seeking Alpha | ||
| 13.08. | Stryker Up 13.6% in 3 Months as Recovery Gains Strength, What's Next? | 12 | Zacks | ||
| 13.08. | Can Stryker's Q2 Recovery and Guidance Support a Stronger Second Half? | 14 | Zacks | ||
| 12.08. | Stryker's (SYK) Comeback Quarter Looks Great, But At What Cost? | 11 | Insider Monkey | ||
| 11.08. | Stryker-Aktie: Startet über 352,65 US$ die nächste Rally? | 782 | sharedeals.de | Die Stryker-Aktie hat sich nach dem scharfen Rücksetzer aus dem Frühjahr deutlich erholt und notiert inzwischen wieder bei 345,81 US$. Damit rückt der entscheidende Widerstandsbereich um 352,65 US$... ► Artikel lesen | |
| 07.08. | If You Invested $100 In Stryker Stock 20 Years Ago, You Would Have This Much Today | 6 | Benzinga.com | ||
| 05.08. | Stryker Corporation: Stryker declares an $0.88 per share quarterly dividend | 433 | GlobeNewswire (Europe) | Portage, Michigan, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable July 31, 2026, to shareholders... ► Artikel lesen |
1 2 3 4 5 Weiter >>
179 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOAFFINITY TECHNOLOGIES | 15,170 | -0,65 % | Morning Market Movers: Ultragenyx Pharmaceutical, bioAffinity Technologies, Tilly's, Inc., Snowflake See Big Swings | BEIJING (dpa-AFX) - At 7:50 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,600 | -0,03 % | Summit Therapeutics Stock Rises 11% | ||
| TARSUS PHARMACEUTICALS | 90,84 | +0,07 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care | Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approved... ► Artikel lesen | |
| TYRA BIOSCIENCES | 28,650 | 0,00 % | Tyra Bio rises on upcoming mid-stage trial readout for bladder cancer drug | ||
| RECURSION PHARMACEUTICALS | 3,635 | +0,14 % | Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook? | ||
| QIAGEN | 36,340 | -0,09 % | Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit | ||
| PRAXIS PRECISION MEDICINES | 352,42 | +0,17 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| VIR BIOTECHNOLOGY | 11,385 | 0,00 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 | - Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in "Best of EASL 2026" by EASL - Poster presentation of Week 48... ► Artikel lesen | |
| VERA THERAPEUTICS | 35,890 | 0,00 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DYNE THERAPEUTICS | 24,270 | -0,04 % | Dyne to present preclinical data on four DMD therapies | ||
| RELAY THERAPEUTICS | 19,060 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 117,48 | +0,08 % | Can KT-621 Mark a Turning Point for Kymera Therapeutics? | ||
| ALUMIS | 11,090 | -0,09 % | Alumis-Aktie: No Brainer Club feiert zweistellige Kursgewinne zum Start | Gewohnt gutes Timing: Der No Brainer Club hat auch bei Alumis im richtigen Moment zugeschlagen und blickt bereits nach einem Tag auf zweistellige Kursgewinne. Nach dem massiven Abverkauf infolge enttäuschender... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 34,140 | +0,12 % | Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%? | ||
| PARABILIS MEDICINES | 40,420 | 0,00 % | Parabilis Medicines, Inc. - 8-K, Current Report |
Das Unternehmen STRYKER CORPORATION CDR kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 12,300 Euro und damit -2,38 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu STRYKER CORPORATION CDR finden Sie auf Wallstreet Online.